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MLPA: Multiplex Ligation dependent Probe Amplification 
NAT2: N-acetyltransferase 2  
NFkB: Nuclear Factor kappa Beta 
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PCR: Polymerase Chain Reaction 
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INTRODUCTION 
Crohn's disease (CD) and ulcerative colitis (UC) are two related diseases that belong to a larger 
group of illnesses called chronic inflammatory bowel diseases (IBD). Studies indicate that the 
inflammation in IBD involves a complex interaction of several factors, among these inherited 
genetic susceptibility, the immune system, and environmental factors. However, relatively little 
is known about genetic risk factors and the interaction between genetic and environmental 
factors.  
 
Inflammatory bowel diseases 
IBD is mainly used to describe CD and UC but other forms such as indeterminate colitis also 
exist. CD and UC are characterised by an abnormal immune response. CD and UC differ by 
both the localisation of and the nature of the disease1. CD usually involves the colon and ileum, 
but may involve any part of the gastrointestinal tract. All layers of the intestine may be involved, 
and there can be normal healthy bowel in between patches of diseased gut. In UC the 
gastrointestinal involvement is limited to the colon and the rectum. The rectum is nearly always 
involved and the lesion extends proximally in a continuous pattern1.  
 
Incidence and prevalence 
The prevalence and incidence of IBD have historically been higher in developed 
countries2;3.The incidence of CD and UC has recently been investigated in different 
geographical regions of Denmark. For women the incidence of CD was approximately 10 pr 
100.000 and for men 8 pr 100.000 in the two regions4;5. The incidence of UC was in the range of 
13-17 pr 100.000 for both men and women in the two distinct regions of Denmark4;5. The 
prevalence of CD and UC was 151 and 294 pr 100.000 inhabitants in Northern Jutland on the 
31st of December 2002, which gave an estimate of 25000 Danish IBD patients5. 
 
Symptoms and diagnosis  
A diagnosis of IBD is usually made in young adults. Two recent Danish studies revealed that the 
majority of IBD diagnoses is made in the period between the late teenage years and into the 
thirties4;5. The diagnosis of CD or UC is established by finding characteristic intestinal 
ulcerations and excluding alternative diagnoses, such as enteric infections. CD patients typically 
present with diarrhoea, abdominal pain, fever and weight loss. UC patients typically present with 
rectal bleeding, diarrhoea, and abdominal pain. Active disease in UC is characterized by the 
endoscopic appearance of superficial ulcerations and bloody stools are common. The diagnosis 
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of IBD can be made only when other reasonable alternatives in the differential diagnosis have 
been excluded6;7. 
 
Treatment and prognosis 
IBD is a chronic disease, but the activity will fluctuate between disease flare-up and times of 
remission. The quality of the social life of a patient may be tremendously affected. Symptoms 
may range from mild to severe, and therapy is dependent on both severity of disease, location 
of disease, and disease associated complications. The medical therapy includes anti-
inflammatory and immunosuppressive drugs and biological drugs6;7. The response to medical 
treatment and tolerance of the medicaments vary greatly between individuals. The main goal of 
disease treatment is to induce remission of disease, and for the patient to remain in remission. 
Colorectal cancer risk is an important concern for patients with UC or CD8. In general, the 
longer a person has had IBD, the greater is the risk of developing colorectal cancer. 
Surveillance using colonoscopy is used to detect early dysplasia in IBD patients.  
 
Genes in complex diseases 
Where monogenic diseases have recognisable inheritance patterns for recessive, autosomal 
dominant and gender-linked diseases which allows for exact calculation of risk of disease, the 
inheritance pattern of complex diseases are less evident. Complex diseases are associated with 
the effects of multiple genes and also in combination with environmental factors such as lifestyle 
factors.  
Genetic risk factors of complex diseases are usually found by association studies. 
Hypothesis generated studies have been used for decades to investigate whether candidate 
genes are associated with disease. The completion of the Human Genome Project revealed the 
human genetic profile to consist of more than 3 billion base pairs. An estimate of between 
20.000-25.000 genes was found which means that only a small percentage (1.0-1.4%) of the 
genome sequence encodes proteins9. The genomes of human individuals are more than 99% 
identical, leaving approximately 1% of the human genome responsible for both normal genetic 
variation and genetic predisposition of diseases. The International HapMap Project, a project 
investigating the genetic variation between populations of different ethnic origin, was conducted 
in parallel with the Human Genome Project9. The information from these studies is used in 
search of genetic predisposition of diseases. The HapMap Project has made an estimate that 
more than 10 million Single Nucleotide Polymorphisms (SNPs) are present in the genome10. 
Many of the polymorphisms are common functional polymorphisms influencing the phenotype of 
the individual. Hence, the polymorphisms are responsible for variations in the population. 
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Common variants vs. rare variants in common diseases 
According to the common disease - common variant hypothesis, the risk of contracting common 
diseases is influenced by genetic polymorphisms that are relatively common in the 
population11;12. Genome Wide Association (GWA) studies has made the search for susceptibility 
genes without any prior assumptions of the genes possible. GWA studies use a large number of 
well-spaced SNPs to provide almost complete coverage of the human genome. The function of 
the disease associated variant is often unknown. The causative gene variant may then be found 
by scanning nearby genes that could possibly be related to the disease of interest. There is also 
the possibility that the common variants may act as modifiers of the effect of other rare 
variants11;12. However, some precautions may be taken. When using the GWA approach very 
large study populations are needed because the variants in general contribute with only a 
modest disease risk. The significance levels must take into account the large number of multiple 
testing to avoid large number of false positives. Replication studies are needed to eliminate 
false positives found in preliminary studies.  
The common disease – rare variant hypothesis argues that rare relatively high penetrant 
genetic variants contribute to common diseases13. For rare variants the functional effect lies 
within the rare variant. The rare variants are often population specific due to the founder effect, 
and replication studies of rare variant associations are difficult because of the rarity of the 
variant. Rare variants are found by sequencing regions in functionally relevant genes. Hence, 
selection of genes to investigate is extremely essential when searching for rare disease causing 
variants.  
GWA studies uncovering common variants vs. trying to identify rare disease associated 
variants are two different ways to identify genetic susceptibility of disease. Pros and cons have 
been made concerning both approaches and the discussion will probably continue in upcoming 
years12;13.  
 
Genes in inflammatory bowel diseases  
A positive family history of IBD is the greatest independent risk factor of developing disease. 
Twin studies have shown a higher concordance rate among monozygotic than among dizygotic 
twin pairs proving a genetic influence on occurrence of IBD. The monozygotic disease 
concordance was approximately 50% for CD and 18% for UC14-18. Thus, the genetic contribution 
to disease seems to be more pronounced with regard to CD than to UC. 
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Disease associated genes 
As IBD is characterized by altered epithelial barrier function and defects in the immune 
response, genes involved in the immune response, especially the innate immune response, are 
likely candidates as risk factors of IBD. Genes that directly or indirectly affect the epithelial 
barrier are also possibly candidates when searching for genetic risk factors of IBD. 
Huge progress has been made in unraveling the genetic background of IBD. The recent 
year’s GWA studies have made an immense contribution to the number of known genetic risk 
factors of IBD, but the contribution to disease risk is in general low. More than 100 loci are now 
known for both UC and CD, where some of them are shared19-21. Many of the identified 
susceptibility genes cluster into known cellular processes of immunity and autophagy22-24. It is 
intriguingly exciting when more than one gene in a pathway is associated with disease 
susceptibility. Several genes involved in the differentiation of the T helper cells Th17 have 
shown to be associated with IBD. Genes such as IL12B, JAK2, STAT3, CCR6 and 
IL23R20;22;25;26. Most of these are shared for CD and UC, but CCR6 are specific to CD23. 
Specific genetic variants in ATG16L1 and IRGM involved in autophagy have shown disease 
susceptibility to CD 22;27;28.  A possible interaction between ATG16L1 and the first identified CD 
susceptibility gene CARD15 strengthen the importance of autophagy related genes in CD29-31. 
Genes involved in epithelial barrier function such as ECM1, LAMB1 have shown susceptibility 
specific to UC and not to CD22;23;26.  
A tremendous job is still ahead unraveling the causal genes and genetic variants within 
susceptibility loci identified by GWA studies.  
 
CARD15 
The innate immune system serves to immediately recognize pathogen associated molecular 
patterns and control infection by inducing pro-inflammatory cytokines and chemokines that 
recruit inflammatory cells32. Pattern recognition receptors are proteins expressed by epithelial 
cells and cells of the innate immune system.  Pattern recognition receptors have a key role in 
maintaining the integrity of the epithelial barrier33;34. Two distinct systems of pattern recognition 
receptors have been investigated in susceptibility to IBD; the membrane bound Toll-Like 
Receptors (TLRs) and the cytoplasmic Nucleotide-binding oligomerisation domain Like 
Receptors (NLRs)35. The receptors initiate immunity by recognizing different molecular patterns 
such as bacteria cell wall components34. 
The TLRs are important initiators of immunity by recognizing different pathogen associated 
molecular patterns shared by bacteria36. The action of TLRs upon recognition of microbial 
patterns is an initiation of a signaling cascade that triggers immunity by a pro-inflammatory 
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pathway37. Several TLRs, TLR2, TLR4, TLR5 and TLR9, have been associated with IBD32;36;38. 
TLR4 is the most intensively investigated TLR with respect to IBD and a large meta-analysis 
have reported two polymorphisms in the gene to cause susceptibility to both UC and IBD in 
Caucasians36. The data suggest that TLRs are crucial for initiation and progression of IBD, but 
mutations in a single TLR gene are insufficient to explain the complex pathogenesis of IBD. 
The NLRs are like the TLRs important in regulation of pro-inflammatory pathways in 
response to bacteria by inducing signaling pathways initiating an immune response39-41. The 
NLRs consist of three domains; a C-terminal leucine rich repeat, a central domain and a 
variable N-terminal domain which is responsible for the diversity of the NLRs42.  
A caspase recruitment domain (CARD) is the N-terminal domain in the NLRs nod1 and 
nod2. These receptors are alternatively named CARD4 and CARD15 due to changes in the 
nomenclature. CARD15 was the first IBD susceptibility gene identified, and it has been found 
only to be a risk factor of CD43;44. Few variations have been reported in African and Asian 
populations, but at least 30 variations may be seen in Caucasians45;46. The majority of variations 
are specific for each individual but three variations occur more frequently and may in some 
populations be considered rather as polymorphisms and not mutations. The three common 
variants are two SNPs and one frame-shift mutation which account for up to 82% of all CARD15 
mutations found46. The three variations are located within the C-terminal region of the protein 
responsible for ligand recognition42. Recognition of bacterial components by CARD15 proteins 
activate the Nuclear Factor kappa Beta (NFkB) pathway which initiates transcription of 
proinflammatory cytokines and antimicrobial peptides such as defensins35;40;47  This is illustrated 
in figure 1 on the following page. 
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Figure 1. Action of CARD15 
CARD15 is activated by binding of degradation products of peptidoglycans (PGNs) derived from 
bacterial cells walls. Their presence triggers CARD15 oligomerisation and recruitment of RIP-like 
interacting CLARP kinase (RICK) via CARD-CARD interaction. RICK then activates 
the nuclear factor kB inhibitor (IkB) kinase complex (IKK) via phosphorylation of IKKc. The IKK complex 
next phosphorylates IkB resulting in nuclear factor kB (NFkB) translocation to the nucleus and 
transcriptional activation of NFkB responsive genes such as proinflammatory cytokines or 
defensins. Modified from Gasche et al47. 
 
The exact mechanism of how CARD15 variations contribute to CD is not fully understood. It has 
been debated whether the contribution to CD pathogenesis happens either through a loss of 
function or a gain of function mechanism. The loss of function explanation relies on a 
diminished response upon recognition of microbial patterns leading to a less effective 
recruitment and function of innate cells. Based on this hypothesis otherwise harmless 
commensal bacteria will increasingly translocate into the intestinal mucosa leading to an 
activation of the adaptive immune system and ultimately a chronic inflammation34. The gain of 
function explanation states initiation of a hyper-response upon recognition of microbial patterns 
leading to an excessive innate immune response, despite of normal levels of microbial patterns 
present34;48.   
Prevalence of the three CARD15 variants have shown great ethnic differences, indicating 
that genetic susceptibility differ between populations of different ethnic origin49;50. Heterogeneity 
exist even between the European countries, i.e. CARD15 variants are less frequent in Northern 
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Europe49;51. Regional diversity of CARD15 variants in Europe indicates the existence of 
selection pressure within a region. Natural selection within a certain geographical region along 
with genetic drift can ultimately lead to elimination, or in this particular case fixation, of a specific 
variant52. 
 
Gene environment interactions 
More than genetic susceptibility is responsible for developing IBD. The environmental 
contribution to IBD is evident by the fact that incidence and prevalence of IBD are increasing in 
areas which have historically been low incident areas20. Environmental factors play a crucial 
role in disease pathogenesis and the interaction between susceptibility genes and different 
environmental factors has been shown to influence the risk of developing IBD53;54. 
All sorts of environmental factors such as breastfeeding, childhood infections, use of oral 
contraceptives, appendectomy, smoking and hygiene have been investigated in search for 
association with IBD53;55-57. Most research has resulted in contradictory results. Appendectomy 
has shown some protective effect against UC53, but the most intensively investigated factor is 
tobacco smoking. Smoking has consistently proven to be a risk factor for CD, while on the 
contrary current smoking has shown to be a protective factor against UC53;55;58;59. Differences in 
associated genes between smoking and non-smoking CD patients point towards complex gene 
environment interactions 53;54;60.   
 
The xenobiotica metabolising enzyme system 
The human body is exposed to a wide array of xenobiotics; from environmental components 
and pharmaceuticals to endogenously produced reactive substances. The body comprises a 
complicated enzymatic biotransformation system which detoxifies these substances61;62. The 
majority of the detoxification reactions take place in the liver but a great amount of detoxification 
occurs in the gastrointestinal tract as well63. The enzymes are highly polymorphic displaying 
wide phenotypic variation. Impaired ability to remove reactive substances from the body may 
play a role in the aetiology of chronic conditions i.e. autoimmune diseases by gene environment 
interactions61.  
The intestinal epithelial barrier constitutes the largest and most important barrier against the 
external environment. The crucial function of the epithelial barrier is to allow absorption of 
nutrients and water, while maintaining an effective defence against luminal toxins and antigens. 
The permeability of the epithelial barrier is regulated by multiple factors such as cytokines, 
immune cells, apoptosis and exogenous factors such as xenobiotics61;64;65. Increased intestinal 
permeability have been shown not only in IBD patients, but also in healthy first degree 
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relatives66-68. Xenobiotica metabolising enzymes and cellular efflux transporters are critical 
components in maintaining intestinal barrier integrity by removing or detoxifying reactive 
metabolites of xenobiotics which make these enzymes candidates as risk factors69. 
The consequence of biotransformation is in most cases detoxification; however, metabolism of 
some xenobiotics generates metabolites that are more reactive than their substrate compound. 
The biotransformation system involves several enzyme systems that are commonly divided into 
two phases; phase I and phase II. The phase I enzymes are responsible for oxidation, reduction 
or hydrolysis and can be either detoxifying or activating63. The phase II enzymes exert primarily 
detoxifying potential by conjugation61. The export of xenobiotics and conjugates out of the cell 
may be considered phase III biotransformation61. The efflux transporters (phase III) mediates 
the transport of xenobiotics and conjugated compounds back into the gut lumen or into the 
lymph for transport back to the liver70;71. The transporters play a pivotal role in drug resistance 
but are also involved in protecting tissue from xenobiotic accumulation and toxicity. Two 
members of this group of transporters were included in the present study; p-glycoprotein 
encoded by MDR1/ABCB1 (MDR1), and the breast cancer resistance protein encoded by 
BCRP/ABCG2 (BCRP)72. Figure 2 depicts the route towards excretion for xenobiotics with 
different characteristics. 
 
Figure 2. The road towards excretion of xenobiotics.  
* denotes enzymes covered in this thesis. 
 
Glutathione S-transferases 
Substrates of the Glutathione S-transferase (GST) enzyme family could be by-products of either 
free radical damage generated during oxidative stress such as fatty acid hydro peroxides or 
diol-epoxide by-products derived from polyaromatic hydrocarbons originating from incomplete 
combustion of tobacco smoking73-77. The GST enzymes share several substrates derived from 
tobacco smoke. Hence, GST genotype may have a modifying effect on smoking. A previous 
study found genetic GST variants encoding low (Glutathione S-transferase π  (GSTP1 105)) and 
missing activity (Glutathione S-transferase µ (GSTM1*0)) to have a modifying effect on smoking 
increasing the level of inflammation78.  
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microsomal Epoxide Hydrolase  
Microsomal Epoxide Hydrolase (mEH) plays an important role in both the activation and 
detoxification of by-products of polycyclic aromatic hydrocarbons from exogenous chemicals 
such as tobacco smoke. Two common functional polymorphisms exist in the mEH gene. One, 
the 113 polymorphic site, resulting in a 40% decrease in enzymatic activity, another, the 139 
polymorphic site, resulting in a 25% increase in enzymatic activity79;80. This phase I 
metabolising enzyme exhibit a dual role and is capable of both detoxification of epoxide 
intermediates and of participating in metabolic activation of intermediates into more reactive 
epoxides81;82. Figure 3 illustrates the dual role of mEH by the metabolisation of benzo(a)pyrene. 
 
 
Figure 3. Metabolisation of Benzo(a)pyrene 
mEH is involved in the metabolisation of two benzo(a)pyrene derived intermediates. The vertical reaction 
to the left leads towards benzo(a)pyrene4,5dihydrodiol, a less reactive molecule. In the horizontal 
reaction mEH gives rise to benzo(a)pyrene7,8dihydrodiol which act as substrate for generation of the 
highly reactive  benzo(a)pyrene7,8dihydrodiol-9,10epoxide. The vertical reaction to the right is the 
detoxifying conjugation reaction with glutathione by an enzyme of the GST family.  
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N-acetyl transferase 2  
The N-acetyltransferase 2 (NAT2) enzyme is important in the biotransformation of a number of 
aryl amines and heterocyclic amines derived from foods, tobacco smoking or other 
environmental substances83. It is possible that individuals with slow NAT2 acetylator status have 
a decreased ability to metabolise xenobiotics leading to accumulation which leads to increased 
permeability in the gastrointestinal tract. The accumulation of xenobiotics are believed to induce 
an autoimmune mechanism and NAT2 slow acetylator status has been shown to be associated 
with autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis and 
diabetes mellitus84-86. A Japanese study has shown an association between NAT2 slow 
acetylator status and CD87. 
 
P-glycoprotein and Breast Cancer Resistance Protein 
The enzymes P-glycoprotein and Breast cancer Resistance Protein (BCRP) function as 
intestinal transporter of xenobiotics and are highly expressed in the gut88;89. P-glycoprotein 
encoded by the Multi Drug Resistance protein (MDR1) gene has shown decreased levels of 
expression in inflamed tissue in active UC89-91. Genetic variants of the MDR1 gene exist and the 
main focus has been on two polymorphic sites in the gene. The two functional genetic variants 
have been shown to correlate with the activity and expression of the enzyme, and the two 
polymorphisms have been associated with IBD in different populations but with conflicting 
results90;92-94.  
BCRP has shown decreased levels of expression in the inflamed mucosa of patients with 
active UC as was the case for p-glycoprotein89;90. BCRP as a possible susceptibility gene of IBD 
has not been as intensively investigated as MDR1. A Hungarian study showed no association 
between two variants of the BCRP gene and IBD95. 
 
Hypothesis 
CARD15 was the first gene found to confer susceptibility to CD43;44. The variations in CARD15 
have shown to display wide ethnic variation, and even display heterogeneity within Western 
populations and between European countries49;51. The CARD15 variants have consistently 
shown to display susceptibility only to CD and not UC28;96. Hence, the hypothesis was that 
CARD15 variations were associated with CD and not with UC in our population, and that 
phenotypic associations would be likely.  
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High levels of oxidative stress along with increased intestinal permeability have been 
observed in IBD97-99. Reactive molecules play a central role in altering the intestinal 
permeability. Hence, impairment in the biotransformation system responsible for detoxification 
of reactive substances might be important in the aetiology of IBD. This led to the hypothesis that 
genetic polymorphisms responsible for low or missing activity of detoxification enzymes are risk 
factors of IBD. This hypothesis is supported by the common disease – common variant 
hypothesis11;12. Polymorphisms in detoxification enzymes have been associated with 
autoimmune disease i.e. systemic lupus erythematosus and rheumatoid arthritis84;86. However, 
only a few contradictory studies have focused on polymorphisms in detoxification enzymes as 
possible risk factors of IBD.  
 
Aims 
The overall objective of this study was to clarify the extent of three relatively common variations 
in the CARD15 gene in susceptibility to IBD in our cohort. It was also intended to make a 
comparison with other Western populations and to determine whether the CARD15 mutations 
were important regarding disease phenotype (study I). The other main objective of this study 
was to estimate the significance of the highly polymorphic xenobiotica metabolising enzymes of 
the GST family (study II), the mEH (study III) and the NAT2 (study III) in susceptibility to IBD in 
our cohort. Whether the polymorphic enzymes were important for disease phenotype and 
whether an interaction with smoking was present was also assessed (I, II, III). 
The aims were: 
1. To assess the significance of three common variations in the CARD15 gene in 
susceptibility to IBD, and to determine whether any genotype-phenotype correlations 
were present. 
2. To assess the significance of having a genotype encoding low or no enzymatic activity of 
Glutathione S-transferase µ (GSTM1), Glutathione S-transferase θ (GSTT1) and 
Glutathione S-transferase π (GSTP1) in susceptibility to IBD, and to determine whether 
any genotype-phenotype correlations were present. 
3. To estimate whether interactions were present between the GST enzymes in 
susceptibility to IBD. 
4. To assess the significance of having the slow acetylator genotype of NAT2 in 
susceptibility to IBD, and to determine whether any genotype-phenotype correlations 
were present.  
5. To assess the significance of low activity genotype of mEH in susceptibility to IBD, and to 
determine whether any genotype-phenotype correlations were present. 
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6. To determine the role of smoking behaviour in susceptibility to CD and UC, and to 
investigate a possible modifying effect of smoking on GST genotypes, NAT2 acetylator 
status and mEH genotypes in susceptibility to CD and UC.  
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METHODS 
Study design 
The present epidemiologic study was conducted as an observational study of the case-control 
type. This was concerned with the frequency of exposure (genotype or smoking) in IBD patients 
(cases) and people without the disease (controls). This type of study is the predominant design 
when searching for aetiology and causal associations in diseases. Association between 
exposure and disease was expressed as odds ratios (OR) which represent the odds of 
exposure in cases divided by the odds of exposure in controls. 
 
Strength and limitations of the study 
A great advantage when choosing the case-control design was the possibility to examine many 
exposures in the same study. A great strength of this study design was that of being able to 
recruit cases fast. Three hundred and eighty-eight patients with CD and 565 patients with UC 
were included in the study. The patients were recruited from the outpatient clinics between 
January 2004 and March 2005 from three Danish hospitals in the cities of Aalborg, Viborg and 
Herning. A senior registrar reviewed the case record and only patients fulfilling the diagnostic 
criteria of CD and UC as proposed by Binder were included100. Patients with indeterminate IBD 
were excluded, and patients under the age of 18 were also excluded from the study.  
The collection of patients was biased by the fact that colectomised patients were not 
included in the study group because these patients no longer attended routine follow-up 
consultations. These patients are estimated to represent 10-15% of the patients. A control 
group of 796 healthy blood donors representative of the general Danish population were 
recruited from Viborg County during the same period. All participating patients and controls 
gave written consent and the local Ethical Committee at Aalborg and Viborg County approved 
the protocol (VN2003/5).   
The purpose of the control group was to provide an estimate of the frequency of genetic 
polymorphisms and smoking status in subjects in the population without the disease. A major 
challenge in the case-control study design was the selection of a representative control group. 
The controls in this study were blood donors recruited at Viborg Hospital. Blood donors tend to 
be healthier than the general population which may be reflected in their genetic profile 
(discussed in paper III). Recall bias is common regarding exposure in case-control studies. In 
the present study genetic polymorphisms represent the exposure, thus recall bias was not an 
issue. Uncertainty of whether the former smokers were smokers at the time of diagnosis, or 
whether they quit smoking prior to being diagnosed with IBD, may have biased the results when 
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separating smoking into three groups of current smokers, former smokers, and never smokers. 
To avoid bias the current smokers and former smokers were grouped together. For a few sub-
analyses the ever smoker group were separated into current and former smokers.  
 
Genotyping assays 
Two different Polymerase Chain Reaction (PCR) based methods were used to determine the 
genotype of the different genes in the individual papers I, II and III. 
 
PCR gel based assays 
Two steps are included in the PCR gel based assays: PCR amplification by use of specifically 
designed primers, followed by visualisation using gel electrophoresis. A housekeeping gene is 
usually used as an internal control of amplification. Primers with similar annealing temperatures 
are designed for the gene of interest as well as the control gene and are run for 35-45 cycles 
depending on the assay.  
            
Real-time PCR based assays 
The real-time PCR assay visualises the exponential PCR amplification as it progresses, 
whereas in traditional PCR, results are collected after the reaction is complete. In real-time PCR 
the quantity of the PCR product is directly proportional to the amount of template.  
 
Allelic discrimination assay  
The real-time allelic discrimination assay was used to genotype SNPs (I, II, III). As for the PCR 
gel based assays a specific set of primers was designed. Besides the primers, two specific 
probes which recognised the two possibilities at the polymorphic site of the gene of interest 
were designed. TaqMan technology from Applied Biosystems was used for genotyping in the 
present studies (I, II, III). The two probes specific for each of the two possible alleles of the 
polymorphic site was labelled with two different fluorescent dyes at the 5´ end (V and F fig. 4). 
The 3´end was labelled with a quencher (Q, fig. 4), which absorbs the fluorescent emission. The 
probe anneals to the DNA sequence complementary to its sequence and it is incorporated into 
the DNA strand. This separates the fluorophore from the quencher and fluorescent emission 
occurs.  
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Figure 4. Taq-Man based allelic discrimination 
Top: Vic-labelled probe recognises its target allele 1 and is incorporated during the amplification of DNA. 
The FAM-labelled probe does not recognise allele 1. Bottom: The FAM-labelled probe recognises its 
target allele 2 and is incorporated during the amplification of DNA. The Vic-labelled probe does not 
recognise allele 2. Figure from manual supplied with the HT7900 Real-time apparatus from Applied 
Biosystems. 
 
This emission represents the amplification of products in real-time. Figure 5 shows a signal for 
both fluorescent dyes. Hence, this sample is heterozygous for the polymorphic site. If the 
sample had been homozygous for either the wild type or the variant, only one curve would 
show. For allelic discrimination assays a scatter plot is produced for each run, which allows for a 
fast check of the results. Figure 6 (on the following page) represents the genotype callings 
made by the system for an allelic discrimination run from the genotyping of NAT2 (III).  
 
          
Figure 5.  Amplification curves of real-time assay 
Amplification curves for a sample being heterozygous for the polymorphic site investigated. Each curve 
represents a signal for one specific fluorescent dye. 
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Figure 6. Allelic discrimination scatter plot 
Scatter plot of allelic discrimination run. Circles in upper left corner represent the wild type genotype, 
circles in the lower right corner represent the homozygous variant genotype, and circles along the 
diagonal represent the heterozygous genotype. The black square is a negative control. The x is a 
genotype not called by the system. 
 
Relative quantification assay 
In the relative quantification real-time assay a target gene and a reference gene are amplified in 
the same tube. For the method to be valid, the efficiency of the target gene amplification and the 
efficiency of the reference gene amplification must be approximately equal. This method 
compares the threshold cycle of one target gene to a reference housekeeping gene in a single 
sample.  
 
Genotyping assays used in the thesis 
Genotyping of CARD15 
The allelic discrimination design was chosen for genotyping of the three common CARD15 
variants (I). The primers and probes used as well as the concentrations and the run parameters 
are described in detail in paper I. Direct sequencing of the three common variants was used for 
validation of the assay using primers from King et al Human Mutation Supll. Online Nov. 2005. 
Another approach for genotyping CARD15 on the entire cohort could be direct sequencing. This 
would have been the method of genotyping if searching for rare private for the genotyping of the 
entire cohort, which would have been the preferable technique if we were searching for rare 
private mutations in our cohort. 
Wild type 
Heterozygous 
Homozygous 
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Genotyping of GSTT1 
The PCR gel based assay was used only to genotype GSTT1 (II).  A primer pair specific for the 
commonly deleted region in GSTT1 was designed. This resulted in an amplification product of 
480 bp when the GSTT1 was present on either one or both alleles. Hence, having the GSTT1*0 
genotype lead to no amplification. A primer pair specific for amplification of a 299 bp product of 
the β-globin gene was used as an internal control of amplification. The primers, reaction mix 
and incubation information are listed in paper II. The PCR products were separated by size 
using agarose gel electrophoresis and visualised by an intercalating dye. Figure 7 shows an 
image from the genotyping of GSTT1 (II).  
 
            
 
Figure 7. Image of the GSTT1 genotyping 
Lanes 1 and 18 showing only the 299 bp β-globin product represents the null variant GSTT1 genotype 
(GSTT1*0). Lanes 2-17, and 19 show both the 299 bp β-globin product and the 480 bp GSTT1 product. 
These individuals are positive for GSTT1, thus they have one or two GSTT1 alleles. Lanes 21-24 are 
positive controls for GSTT1. Lane 25 is a molecular size marker. The signals from lane 13, 15 and 20 
were weak and the samples were repeated. 
 
Genotyping of GSTM1 
An in-house PCR gel based technique was available for genotyping of GSTM1 but the assay 
was not as robust as for GSTT1. The annealing temperature had to be changed constantly and 
it was difficult to interpret the result from the gel image. Hence, it was decided to use a real-time 
PCR based assay for genotyping GSTM1 to make sure the results were valid.  
This design was used for genotyping of GSTM1 which exhibit a variant where the entire 
gene is deleted101 (II). The method is somewhat similar to the allelic discrimination method but 
in this study one of the labelled probes anneal to the GSTM1 gene, if present, and the other 
probe to a reference gene. With this type of assay determining copy number variation is 
possible, but we did not use this opportunity. The first published improved real-time PCR 
methods to determine copy number variation in GSTM1 and GSTT1 relied on the use of fixed 
concentrations of sample DNA and triple determinations of each sample102;103. For the present 
study the main interest was to identify the persons homozygous for the GSTM1 deletion variant 
1   2   3   4   5   6    7   8    9  10  11  12 13 14  15 16 17 18  19  20  21 22  23 24 25 
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(GSTM1*0) and no discrimination were made between copy number variation of GSTM1 (being 
homozygous or heterozygous for the GSTM1 allele) (II). Thus, only single determination was 
necessary. Recently a high-throughput single determination genotyping method of copy number 
variation was published104. The determination of copy number variation in GSTM1 could 
become relevant for future studies examining the role of GSTM1 genotype in relation to adverse 
effects of azathioprine treatment in IBD patients105;106. Another approach to determine the copy 
number variation of GSTM1 is to use the Multiplex Ligation dependent Probe Amplification 
(MLPA) by MRC-Holland which offers a panel containing several xenobiotica metabolising 
enzymes107. 
 
Genotyping of GSTP1 
The allelic discrimination design was chosen for genotyping of the two specific GSTP1 
polymorphic sites (II). The primers and probe sequences are listed in paper II. The reaction set-
up and run parameters were identical to those for the CARD15 genotyping and are also 
described in paper II. 
 
Genotyping of mEH 
For genotyping of the two mEH polymorphic sites the allelic discrimination design was chosen 
(III).  Commercially available assays from Applied Biosystems specific for the two polymorphic 
sites were used and the run parameters are listed in paper III. The allelic discrimination assay 
was chosen in preference to a conventional PCR gel based assay due to a report of genotyping 
errors from a PCR based assay in a previous publication108. This publication showed an 
association between low activity of mEH and CD. Due to a questioning of their results the group 
came up with a reanalysis of their cohort using a real-time PCR based assay and was not able 
to reproduce the positive association between low activity of mEH and CD109;110.  
 
Genotyping of NAT2 
The NAT2 genotypes can be divided into three phenotypic categories of rapid, intermediate and 
slow acetylators. The NAT2 acetylator status is determined by a number of SNPs. A 
combination of six relatively common SNPs in NAT2 was used to decide the acetylator status in 
study III. Haplotype determination for the large study group used in this thesis was laborious. 
The haplotype determination was performed by hand, but in many cases several haplotypes 
were possible. The NAT2PRED web server is an extremely useful tool in assigning individual 
acetylator status from the SNPs without having to determine the haplotypes111. The NAT2PRED 
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is based on a dataset of 1377 individuals (94% Caucasians). The performance was high with 
sensitivity and specificities ranging between 99.6 and 100% for determining the three acetylator 
phenotypes111. The ability of the NAT2PRED web server has been assessed by a study 
including 8489 individuals from 56 populations with different geographic origin112. The 
conclusion from this study was that the server correctly identified the slow acetylator phenotype 
with more than 99% sensitivity in all populations outside Sub-Saharan Africa where another 
variant, the 191 G>A SNP, plays an important role113. The classification error rate found in the 
evaluation study implied that the NAT2PRED is poor at distinguishing between fast and 
intermediate acetylators. The classification error rate was though not high in European 
populations112. The data were submitted for each of the six SNPs for all the participants in this 
study and the results were returned by email. The results listed the probability of all three 
acetylation phenotypes for each individual. The intermediate and fast acetylators were grouped 
for data analysis in our study as suggested by the NAT2PRED evaluation study112.  
Table 1 depicts the acetylation calls (prediction) for 10 samples from our cohort. The prediction 
for index 10 was not very secure. In total 7 of 1716 calls were in the range of 0.5-0.6 all 
resulting in a rapid genotype call. (See Table 1 footnotes for further information). 
 
Table 1. Acetylation callings from the NAT2PRED webserver 
index genotype p(R) p(I) p(S) prediction 
      
1 1,1,1,1,1,1 0.97995 0.01221 0.00784 R 
2 3,1,1,3,1,1 0.00116 0.00126 0.99758 S 
3 3,1,1,3,1,1 0.00116 0.00126 0.99758 S 
4 1,3,3,1,3,1 0.00164 0.00118 0.99718 S 
5 1,3,2,1,3,1 0.00164 0.00118 0.99718 S 
6 1,3,3,1,3,1 0.00164 0.00118 0.99718 S 
7 1,2,2,1,2,1 0.00100 0.99696 0.00203 I 
8 3,2,2,1,2,2 0.00001 0.00126 0.99874 S 
9 1,3,3,1,3,1 0.00164 0.00118 0.99718 S 
10 1,1,2,1,1,1 0.61518 0.14525 0.23957 R 
      
      
 
Index is the number of the individual. Genotype cover the genotypes for each of the six polymorphic sites separated by a 
comma: 1 is wildtype homozygous, 2 is heterozygous, 3 is homozygous for the variant. p(R), p(I) and p(S) are the probabilities 
for the three callings Rapid, Intermediate and Slow acetylator status. Prediction is the actual call made by the server: R=Rapid, 
I=Intermediate and S=Slow. The results were returned by email. 
 
Genotyping of MDR1 and BCRP 
Genotyping of MDR1 and BCRP on our study population was performed by one of our 
collaborators, MSc. PhD, Mette Østergaard at Viborg Hospital. An allelic discrimination assay 
was used to genotype the polymorphic sites G2677T/A and C3435T and intron variant G-
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rs3789243-A SNPs of MDR1 and C421A in BCRP. The primers and probes used are listed in 
table 2 which is a modified version from the original paper72. The concentrations and annealing 
temperatures are also described in table 2. The allelic discrimination was performed in a 25 ml 
reaction volume containing 1XTaqMan Universal Master Mix (Applied Biosystems,Foster City, 
Calif., USA), primer and probe concentrations were as described in table 2, and 1µl DNA was 
added. The reaction conditions were: 2 min at 50ºC, 10 min 95ºC, followed by 50 cycles of 20 s 
denaturation at 95ºC, 60 s annealing/elongation at an assay-specific temperature, according to 
table 2.  
Genotype controls were selected among control samples and verified by sequencing 
analyses, using the BigDye Terminator v3.1 Cycle Sequencing kit  from Applied Biosystems 
according to the manufacturer’s recommendations. For each SNP, 20 samples randomly 
selected within each of the three genotype groups were repeated to confirm reproducibility. 
Deviant amplification plots and dual-colour scatter plots in MDR1 2677 runs were repeated and 
then subjected to sequencing analysis in order to analyse for the presence of the rarer 2677A 
variant. 
 
Table 2. Genotyping of MDR1 and BCRP 
Primers and probes 
Concentration 
Primer/Probe 
(nM) 
Annealing 
temperature 
(ºC) 
    
MDR1-2677forward 5´GTTGTCTGGACAAGCACTGA   
MDR1-2677reverse 5´ATCAATCATATTTAGTTTGACTCACC 300/150/100* 60 
MDR1-2677G HEX-CCAGCACCTTCTAGT-BHQ1   
MDR1-2677T FAM-CCCAGAACCTTCTAGTT-BHQ1   
    
MDR1-3435forward 5´GCCTATGGAGACAACAGCCG   
MDR1-3435reverse 5´CGATGAAGGCATGTATGTTGGC 300/200 62 
MDR1-3435C HEX-AAGAGATCGTGAGGGC_BHQ1   
MDR1-3435T FAM-AAGAGATTGTGAGGGC_BHQ1   
    
Grs3789243A forward 5´ACCTTACAAATAAGTCTCAACATTCTCTG   
Grs3789243A reverse 5´CCCAGACAATAAGCCCAAGATCC 900/200 62/72** 
rs3789243G HEX-AACGACGCCCCATAA-BHQ1   
rs3789243A FAM-CAACGACGCTCCATAAATT-BHQ1   
    
BCRP-421forward 5´ATGTTGTGATGGGCACTCTG   
BCRP-421reverse 5´CATGATTCGTCATAGTTGTTGCA 300/150 62 
BCRP-421C HEX-AAACTTACAGTTCTCAGCA_BHQ1   
BCRP-421A FAM-AAACTTAAAGTTCTCAGCA_BHQ1   
    
    
 
BHQ=black hole quencher. Reaction concentration of primers and probes, as well as the annealing/elongation temperature are 
given. *Wild-type-specific probe 150 nM, variant (mutant)-specific probe 100 nM; **elongation was split in the MDR1 rs3789243 
assay; annealing at 62ºC for 30 s, followed by elongation at 72ºC for 30 s. Primers were purchased from DNA Technology 
(Aarhus, Denmark) and probes from Proligo. The reactions were run on a Stratagene Mx3000 machine (Stratagene, La Jolla, 
Calif., USA), using the allelic discrimination feature of the MxPro software (Stratagene). 
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RESULTS - RISK FACTORS OF IBD 
Smoking  
Smoking has been found to be an independent risk factor of CD and current smoking to have a 
protective effect against UC, which was also true for this study population58;59(I). Ever smoking 
was associated with CD with an OR of 1.8 (1.4-2.3), (P<0.001), whereas current smoking had a 
protective effect against UC with an OR of 0.7 (0.5-0.9), (P=0.015) (Table 3). The score of the 
ORs were similar to what has been found in a large number of studies114. Extensive research 
has been made concerning the dual effect of smoking on IBD. A recent publication shared some 
thoughts as to why current smoking has a protective effect against UC55. Intestinal permeability 
is known to be high in UC patients67. The mucus thickness has shown to be shallower in UC 
compared with CD55. Nicotine has shown to enhance mucosal production, thus this could 
possibly strengthen the epithelial barrier in UC hereby decreasing the intestinal permeability55. 
Smoking reduces rectal blood flow, which may cause less recruitment of pro-inflammatory 
mediators to the rectum, thus protecting against sustained inflammation. 
 
Table 3. Association between smoking behaviour and IBD in the cohort. 
Smoking status OR (95%CI) P-value 
 CD UC 
Ever smoker 1.8 (1.4-2.3) P<0.001 1.1 (0.9-1.4) P=0.28 
Current smoker  2.6 (2.0-3.5) P<0.001 0.7 (0.5-0.9) P=0.015 
   
   
OR=Odds ratio, 95%CI=95% confidence interval, P =P value. 
CD=Crohn´s disease, UC=Ulcerative colitis. 
 
CARD15 
We found that harboring at least one CARD15 variant to be associated with CD but not UC in 
the Danish population (I). The OR for a CD patient carrying one CARD15 variant was 1.9 (1.3-
2.8), P<0.001 (I).  A gene-dosage effect was observed in the population raising the OR to 21.1 
(4.9-91.2), P<0.001 for carrying two CARD15 variants (I). In comparison the ORs were 2.4 (2.8-
8.0) and 6.7 (4.1-10.9) respectively in a large meta-analysis of 79 studies (in which our study 
was also included)115. The confidence interval for carrying two variants was wide in our study 
compared with that of the meta-analysis. These numbers suggest that the OR of 6.7 for CD 
patients carrying two variants is more likely than our OR of 21.1 (Table 4). 
The susceptibility to CD is inherent in the R702W SNP and in the 1007insC frame-shift 
mutation, whereas the rare G908R SNP was not associated with CD in our population (I).  
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The frequencies of the three variants in the control group of our population was similar to those 
of a recent publication of more than 38 000 healthy Danes (Table 4)116. When comparing the 
frequencies with a meta-analysis of 3500 healthy Caucasians our findings are similar to the 
findings in other Northern European countries, which in general has a lower CARD15 variant 
frequency than other European countries49. 
 
Table 4. Distribution of CARD15 variants in the Danish population 
CARD15 variants n, (%) 
 CD UC HC 
Ernst et al (I)    
R702W alleles *40 (5.5) 36 (3.3) 44 (2.8) 
G908R alleles 11 (1.5) 9 (0.8) 16 (1.0) 
1007insC alleles **46 (6.4) 12 (1.1) 19 (1.2) 
    
0 variant          365 (79.4) 504 (89.8) 718 (90.3) 
1 variant          ^61 (15.9) 56 (10.0) 75   (9.4) 
2 variants         ^^18 (4.6) 1 (0.2) 2   (0.3) 
Least 1 variant          ^^^79 (20.6) 57 (10.2) 77   (9.7) 
    
Yazdanyar et al 2009116     
0 variants            38592 (87.0) 
1 variant            4838 (12.5) 
2 variants           164   (0.4) 
Least 1 variant            5002 (13.0) 
    
    
*R702W allele frequency in CD patients versus controls: OR=1.9 (1.3-3.0) P=0.02.  
**1007insC allele frequency in CD patients versus controls: OR=5.3 (3.1-9.1) P<0.001.  
^CARD15 1 variant genotype frequency in CD patients versus controls OR=1.9 (1.3-2.8) P<0.001.  
^^CARD15 2 variants genotype frequency in CD patients versus controls OR=21.1 (4.9- 91.2) P<0.001.  
^^^CARD15 at least 1 variant genotype frequency in CD patients versus controls OR=2.4 (95% confidence 
interval (1.7-3.4) P<0.001). OR=Odds ratio, 95%CI=95% confidence interval, P =P value. 
CD=Crohn´s disease, UC=Ulcerative colitis. 
 
Compatible with the high expression of CARD15 in the Paneth cells of the ileum, the 
CARD15 variants were associated with ileal involvement in CD. The OR was 2.6 (1.5-4.5), P= 
0.001, for carrying at least one CARD15 variant (I). When considering the three CARD15 
variants separately, the association with ileal involvement of CD reached only statistical 
significance for the 1007insC frame-shift mutation (I). This association between CARD15 
variants and disease location in CD patients have been demonstrated in the majority of 
association studies117-120. A weak association was found between CARD15 variants and less 
than 40 years of age at disease onset with an OR of 2.0 (1.0-4.0), P=0.038. Smoking was found 
to confer risk of CD and to display a protective effect of UC, but no modifying effect of smoking 
on CARD15 genotype was found for either CD or UC (I). Summarised study I found an 
association between two relatively common CARD15 variants (R702W and 1007insC) and CD. 
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The association was strongest for the 1007insC mutation and a gene-dosage effect was 
observed. CARD15 seemed to influence disease phenotype by affecting disease onset and the 
1007insC variant was associated with ileal involvement in CD. No direct association or 
phenotypic associations was found between CARD15 variants and UC (I). 
 
Xenobiotica metabolising enzymes 
 
Glutathione S-transferase family  
Genotyping of GSTM1 resulted in very similar frequencies within the three groups of CD 
patients, UC patients and healthy controls in our population (II) (Table 5). The findings were 
similar to the findings in three previous European studies108;121;122 (Table 5). An Indian study 
found a significant association between GSTM1*0 and UC123. The frequency of the GSTM1*0 
genotype in the Indian UC patients (61%) was similar our study group (53%), but the difference 
appear to reside in the control populations where the GSTM1*0 genotype has shown to be less 
frequent in the general Indian population (30%)124;125. (Table 5). 
The frequencies of the Glutathione S-transeferase θ null variant genotype (GSTT1*0) were 
also similar between the three groups of CD, UC and healthy controls in our population (II) 
(Table 5). Higher frequencies of GSTT1*0 were found in two previous European study 
populations (II). The GSTT1*0 frequency is generally lower in Scandinavian populations, thus, 
the outcome of the studies were the same, with no difference in GSTT1*0 frequency between 
IBD patients and healthy controls108;121;126. In the previously mentioned Indian study a strong 
association was found between GSTT1*0 and both UC and IBD123. Ethnic differences are 
expected in susceptibility genes, but the fact that very few IBD patients were recruited in the 
Indian study could very likely have biased the results. Further research into whether GSTM1*0 
and GSTT1*0 genotypes are truly associated with IBD in the Indian population are needed. 
The distribution of GSTP1 low activity genotypes (GSTP1 105 low and GSTP1 114 low) 
found in our cohort, were in agreement with previous findings in Caucasian populations108;126 
(Table 5). Research regarding other diseases has shown GST genotypes to be risk factors of 
disease only when present in combination and not as a single gene73. Hence, it could be 
expected that combinations of several of the GST genotypes might be necessary to induce 
susceptibility to IBD. However, no association was found between any combination of having 
GSTM1*0, GSTT1*0 and GSTP1 low activity genotypes and IBD in our study (II). 
Early onset disease has been associated with high familial prevalence of CD, hence, 
suggesting a stronger genetic contribution in this group of patients15;51;127. We were not able to 
replicate a Swedish finding of an association of GSTM1*0 and early onset of UC122. With regard 
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to phenotypic association in general we found no association between GST genotypes and the 
phenotypic behaviours of early onset of disease, localisation of disease and severity of disease 
in our study population (II). Neither did we find any indication of GST single gene or a 
combination of several of the GST genotypes to cause susceptibility to IBD in our study 
population (II). Hence, GST genotypes do not seem to play an important role in susceptibility to 
IBD.  
 
Table 5. GST genotypes among IBD patients and healthy controls in different populations 
 
 
 
CD=Crohn´s disease. UC=ulcerative colitis. HC=healthy controls.  
GSTM1*0:GSTM1 null genotype.  
GSTT1*0: GSTT1 null genotype.  
GSTM1*0 & GSTT1*0: GSTM1 null and GSTT1 null genotype.  
*only percentages available in paper. 
 
 
By-products from tobacco smoke are likely substrates of the GST enzymes and current smoking 
seems to have a protective effect against UC. This was supported in the current study where an 
interaction was found between GSTM1*0 and smoking for UC patients, with GSTM1*0 genotype 
strengthening the protective effect of smoking (II). One might speculate the GSTM1 active 
genotype could eliminate or reduce the protective effect of smoking in UC, whereas the 
GSTM*0 genotype does not interrupt the protective effect of tobacco smoking.  
 
Genotype Distribution of GST genotypes n, (%) 
 CD UC HC 
GSTM1*0        
Ernst et al (II) 215 (56) 296 (53) 417 (53) 
Hertervig122 65 (60) 101 (56) 219 (49) 
Duncan et al121 68 (62) 112 (49) 203 (54) 
De Jong et al108 82 (54)  74 (50) 
Mittal et al123 9 (45) 52 (61) 49 (30) 
    
GSTT1*0    
Ernst et al (II) 66 (17) 82 (15) 104 (13) 
Duncan et al121 17 (16) 52 (24) 47 (18) 
De Jong et al108 23 (15)  30 (20) 
Mittal et al123 18 (90) 77 (91) 26 (16) 
    
GSTM1*0  
&GSTT1*0                
Ernst et al (II) 36   (9) 44   (8) 50   (6) 
Duncan et al121  10 (13)  
De Jong et al108 *(7)  *(13) 
Mittal et al123 4 (20) 28 (33) 8   (5) 
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N-acetyltransferase 2  
We were not able to replicate a Japanese finding of a positive association between NAT2 slow 
acetylator status and CD(III)87. In our study the frequency of NAT2 slow, intermediate and rapid 
acetylators was in agreement with the findings from another Caucasian study population (II)128. 
Highly different frequencies of NAT2 acetylator status are found between different ethnic 
groups. The NAT2 rapid acetylator genotype is present in less than 10% in Caucasian 
populations and in populations of African descent129;130. The NAT2 slow acetylator genotype 
varies between 50-65% in these populations131(III). In Asian populations the NAT2 slow 
acetylator genotype is less frequent ranging between 10-25% but with great differences 
between countries131 (Table 6).  An overrepresentation of NAT2 slow metabolisers have been 
shown among aryl-amine exposed bladder cancer patients compared with healthy controls in 
Caucasian populations131. In contrast, the NAT2 slow metabolisers have been shown to be 
underrepresented among aryl-amine exposed bladder cancer patients in a Chinese population. 
This indicates that pathways other than NAT2 could be involved in the metabolism of aromatic 
amines132. This example demonstrates that genetic risk factors may only be risk factors in some 
ethnic populations not only because of interaction with environmental exposure differences, but 
possibly also depending on the general prevalence of the genetic variant in the given 
population.  
 
Table 6. NAT2 acetylator status in healthy controls of different populations 
NAT2 acetylator status in healthy controls of different populations n, (%) 
(Origin of population) Rapid       Intermediate Slow 
    
Ernst et al (II) (Caucasian) 44 (6) 300 (38) 443 (56) 
Kiyohara et al84 (Japanese)    ^(30)        ^(49)       ^(21) 
Inatomi et al131 (Japanese)*      10   (7) 
Su et al131 (Taiwan)*     13 (13) 
Kim et al131 (Korean)*     24 (11) 
    
    
* Taken from Golka et al131 ^only percentages avaliable in paper 
 
We found no evidence of NAT2 playing a key role in phenotypic characteristics of disease 
regarding either UC or CD (III). Nor was any interaction between NAT2 and smoking found in 
susceptibility to IBD (III). In conclusion, NAT2 does not seem to be important in susceptibility to 
IBD in the Danish population (III).  
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microsomal Epoxide Hydrolase  
We found no association between either of the two mEH polymorphic sites 113 or 139 or a 
combination of the polymorphisms with IBD (III) (Table 7). The findings are in agreement with 
two previous European studies using the same genotyping procedure109;110.  
 
Table 7. Distribution of mEH genotypes 
 
 
 
 
 
 
 
 
 
 
 
 
                    
CD=Crohn´s disease. UC=Ulcerative colitis. HC=Healthy controls. 
Percentages may not add up to exactly 100% due to rounding. 
 
 
The dual role of mEH meant that we had to consider the possibility of both low and high activity 
mEH genotypes as possible risk factors. Analysing the mEH high activity genotype against low 
and intermediate activity genotypes an association with diagnosis of CD before age 40 was 
found with an OR of 2.2 (1.1-4.2), P=0.02. The association was expected to be stronger among 
smokers, because of the dual role of mEH towards benzo(a)pyrene of tobacco smoke, but when 
analysing ever smokers isolated the association did not reach statistical significance (II). This 
finding could possibly be biased by the small numbers in this sub-grouping of patients. Thus, 
the results indicate that mEH may influence the age at disease onset among CD patients but 
further research on a larger population is needed to clarify this. No other phenotypic 
associations were found.  
Dealing with mEH a trend towards a modifying effect of smoking on low mEH activity 
genotype was found for both CD and UC patients. Thus, smokers with a low activity mEH 
genotype may have a higher risk of developing IBD compared with never smokers (III).  Hence, 
mEH may be important in susceptibility of IBD in combination with environmental factors. 
  
Xenobiotic transporters MDR1 and BCRP 
In the xenobiotica transporter gene MDR1 two functional polymorphic sites were genotyped, the 
G2667T/A and C3435T variants, and an intron-variant G-rs3789243-A72. No association was 
 mEH polymorphic sites (n, (%)) 
 mEH 113 genotypes mEH 139 genotypes 
 High          Intermediate         Low  High          Intermediate         Low 
CD  177 (47) 167 (44) 36 (9) CD  21 (6) 118 (32) 235 (63) 
UC 286 (52) 225 (41) 42 (8) UC 25 (5) 190 (35) 335 (61) 
HC 373 (47) 359 (45) 61 (8) HC 42 (5) 284 (36) 466 (59) 
        
 mEH combined genotypes  
 High          Intermediate         Low     
CD  67 (18) 166 (44) 142 (38)     
UC 101 (19) 278 (51) 167 (31)     
HC 156 (20) 363 (46) 274 (35)     
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found between the two functional variants, G2667T/A and C3435T, and either UC or CD72. The 
intron-variant G-rs3789243-A was weakly associated with CD which was in contrast to the 
associative finding with UC found in a Scottish study94 (Table 8). Combining the three variants 
into different haplotypes did not reveal an association with IBD either. Encouraged by the 
conflicting findings regarding MDR1 as a susceptibility gene of IBD, two meta-analyses have 
been made both showing the C3435T polymorphic site to influence susceptibility to UC but the 
effect is small133;134 (Table 8). The two meta-analyses failed to show an association between the 
tri-allelic G2677T/A polymorphic site and IBD. No disease phenotypic associations were found 
for the genetic variants in the meta-analyses. The findings indicate that the contribution to IBD 
from the MDR1 gene may vary among different populations and may also be dependent on 
population specific environmental factors135.  
Our study was confirmative of these findings with very similar allele frequencies of the MDR 
polymorphic variants investigated. The BCRP variant investigated was not associated with IBD 
supporting the Hungarian study, hence BCRP does not seem to play an important role in 
aetiology of IBD72;95. 
 
Table 8. Associations between MDR1 variants and IBD. 
MDR1 variant OR (95%CI) P-value 
 CD UC 
C3435T   
Østergaard, Ernst et al72 0.8 (0.6-1.1) P=0.12 0.8 (0.6-1.1) P=0.15 
Onnie133          1.0 (0.9-1.1) P>0.05 1.1 (1.0-1.2) P=0.013 
Annese134        - 1.1 (1.1-1.3) P=0.003 
   
G-rs3789243-A   
Østergaard, Ernst et al72 1.4 (1.0-1.9) P=0.05 1.3 (1.0-1.5) P=0.09 
Ho et al94 1.2 (0.7-2.0) P=0.67 1.8 (1.1-2.9) P=0.04 
   
   
          OR=Odds ratio, 95%CI= 95% confidence interval, P =P value. 
                CD =Crohn´s disease, UC=Ulcerative colitis. 
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CONCLUSION AND PERSPECTIVES 
 
The frequencies of the CARD15 variants were similar to the findings from other Northern 
European countries. Harbouring at least one of three common CARD15 variants was 
associated with CD but not UC in the Danish population, and a stronger association was found 
for being homozygous for the CARD15 variants compared with being heterozygous (I). The 
susceptibility was inherent in two of the three common CARD15 variants, the R702W and the 
1007insC, the latter displaying the strongest susceptibility to CD. CD patients carrying at least 
one CARD15 variant were more likely to have ileal disease than CD patients with no CARD15 
variants (I). A weak phenotypic association was found between carrying at least one CARD15 
variant and early onset CD (I). No disease susceptibility and no phenotypic associations were 
found between CARD15 and UC (I). Smoking was found to confer risk of CD and current 
smoking to be a protective factor of UC, but no modifying effect of smoking on CARD15 
genotype was found for either CD or UC (I).  
GSTM1, GSTT1 and GSTP1 did not confer susceptibility to either CD or UC, and no 
disease phenotypic associations were found (II). Combining members of the GST family did not 
reveal any association with either CD or UC (II). A modifying effect of smoking was found on 
GSTM1 genotype. Harbouring the GSTM1*0 genotype seemed to strengthen the protective 
effect of current smoking with regard to UC (II). 
NAT2 did not confer susceptibility to either CD or UC and no disease phenotypic 
associations were found (III). No modifying effect of smoking was found on NAT2 acetylator 
status, thus NAT2 does not seem to play an independent role in IBD (III). 
No association was found between either of the two polymorphisms in mEH or the 
combined mEH genotype and IBD (III). One possible phenotypic association was found, that of 
mEH high activity genotype and early onset CD (III). An indication of a possible modifying effect 
of smoking on mEH genotype was found for both CD and for UC (III).  
 
Perspectives 
It is a general opinion that IBD is based on a dysfunctional immune response, but the exact 
mechanism is unknown. Increased intestinal permeability also plays an important role in IBD but 
one might speculate what comes first; intestinal permeability leading to enhanced bacterial 
sensing which induces an immune response, or an exaggerated immune response which 
results in a great production of reactive by-products which may alter the intestinal barrier? The 
extremely complicated nature of the immune system makes it very difficult to find isolated 
genetic variants which contribute independently to disease pathogenesis. This particular thesis 
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focused on genetic susceptibility from variants in enzymes of the xenobiotica metabolising 
system, which is also a very complicated system comparable with the immune system. A 
combination of various genetic variants is possibly responsible for the genetic susceptibility to 
IBD and individual genetic variants confer only a modest disease risk which may be very difficult 
or impossible to demonstrate. Environmental factors also have a substantial role in disease 
susceptibility to complex diseases. Exposure to environmental factors might be very difficult to 
measure which further complicates the finding of true risk factors of IBD. IBD is currently 
emerging in Asia which leaves us with a great opportunity to investigate the shift in 
environmental exposures in that part of the world. Hopefully this will add knowledge to how 
environmental factors influence disease aetiology. The CARD15 variants have shown 
susceptibility to CD only in the Western world and not in the Asian world. This indicates that the 
genetic susceptibility to IBD differ in different populations. Identification of specific genetic 
susceptibility genes is important and may help decode the pathways essential to disease 
pathogenesis. The many susceptibility genes that have been uncovered from the GWA studies 
have shown to participate in specific pathways, which may lead to a better understanding of the 
disease and may also improve the treatment. The xenobiotica metabolising enzymes 
investigated in this thesis did not prove to cause susceptibility to IBD. This may however, be 
important in predicting which patients might develop adverse effects in response to treatment 
with certain pharmaceuticals. GSTM1 has demonstrated its importance in relation to adverse 
effects of treatment with pharmaceuticals containing azathioprine105;106. Looking for copy 
number variation in GSTM1 in relation to adverse effects of azathioprine treatment is something 
we plan to investigate in the near future. NAT2 slow acetylator status has shown to be 
associated with adverse effects of sulfasalazine treatment of IBD in Asian populations136;137. We 
already have the NAT2 acetylator status of the large group of IBD patients included in this 
thesis and we will probably look into this also.  
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SUMMARY IN DANISH 
Kronisk inflammatorisk tarmsygdom dækker over sygdommene colitis ulcerosa og morbus 
Crohn. Studier har vist, at en række faktorer er involveret i inflammationsprocessen ved kronisk 
inflammatorisk tarmsygdom. Medfødt genetisk prædisposition, immunsystemet og 
miljømæssige elementer er alle medvirkende faktorer i udvikling og forløb af sygdommene. 
Sygdommene har historisk set været en byrde overvejende i den vestlige verden, men de 
seneste årtier har incidensen været stigende i Asien. Den hurtige stigning tydeliggør 
betydningen af miljømæssige påvirkninger i ætiologien af kronisk inflammatorisk tarmsygdom.  
Variationer i CARD15 genet, der koder for et protein der genkender bakteriedele, var det 
første gen der viste sig at prædisponere til morbus Crohn, men ikke til colitis ulcerosa. De 
seneste års intensive genom associations studier har bidraget betydeligt med nye genetiske 
risikofaktorer. Nogle af disse gener er fælles for sygdommene, men flere er specifikke for enten 
colitis ulcerosa eller morbus Crohn. Desuden viser flere studier, at der er store etniske forskelle 
i udbredningen af de fundne genetiske risikomarkører. Tre varianter i CARD15 genet der 
prædisponerer for morbus Crohn er eksempelvis ikke nær så hyppige i Skandinavien 
sammenlignet med andre europæiske lande, og er ikke til stede i Asien. Der er også store 
etniske forskelle i miljøpåvirkninger, hvilket gør det kompliceret at finde sande genetiske og 
miljømæssige risikofaktorer. Tobaksrygning er den bedst undersøgte miljømæssige faktor. Det 
har vist sig at rygning forøger risikoen for at udvikle morbus Crohn, men at det har en 
beskyttende effekt mod udvikling af colitis ulcerosa.  
I et case-control studie undersøgte vi hyppigheden af tre CARD15 variationer i den danske 
befolkning. To af de tre hyppige variationer var associeret med morbus Crohn, men var ret 
sjældne i Danmark sammenlignet med andre europæiske lande.  
Patienter med kronisk inflammatorisk tarmsygdom har en øget permeabilitet over tarmvæggen. 
Det ledte til vores hypotese om at en lav aktivitet af enzymer, der omsætter fremmedstoffer 
lokalt i tarmen, kunne forårsage skade på tarmepitelet. Dette var en mulig risikofaktor for 
udvikling af kronisk inflammatorisk tarmsygdom. Flere af disse enzymer (samlet under 
betegnelsen xenobiotika metaboliserende enzymer), har hyppige gen polymorfier der påvirker 
enzymaktiviteten. Vi undersøgte om nogle af disse polymorfier var associeret med kronisk 
inflammatorisk tarmsygdom i Danmark, men vi fandt ingen evidens for at det var tilfældet. Vi 
undersøgte også for en mulig interaktion mellem gen polymorfierne og rygning. Vi fandt enkelte 
genvariationer, hvor der var en risikoforskel for rygere og ikke rygere. Eksempelvis fandt vi en 
genvariation kodende for manglende aktivitet af et enzym (GSTM1), der forstærkede den 
beskyttende effekt af rygning på udvikling af colitis ulcerosa. 
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CARD15 variationer er altså ikke særligt udbredte i Danmark, men de prædisponerer til 
udvikling af morbus Crohn. Generelt set kunne vi konkludere, at genetiske polymorfier i 
xenobitotika metaboliserende enzymer ikke ser ud til at spille en afgørende rolle for udvikling af 
kronisk inflammatorisk tarmsygdom. Enzymerne er vigtige i omsætningen af medikamenter 
brugt til behandling af kronisk inflammatorisk tarmsygdomme. Det kan betyde at bestemmelse 
af genetiske polymorfier i xenobitika metaboliserende enzymer er relevant i forbindelse med 
medicinsk behandling af sygdommene og fremtidige studier er planlagt for at afdække dette. 
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